Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Leases (2019 - 2025)

Heron Therapeutics filings provide 7 years of Current Leases readings, the most recent being $780000.0 for Q3 2025.

  • On a quarterly basis, Current Leases fell 75.99% to $780000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $780000.0, a 75.99% decrease, with the full-year FY2024 number at $3.0 million, down 1.24% from a year prior.
  • Current Leases hit $780000.0 in Q3 2025 for Heron Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.3 million in Q3 2021 to a low of $780000.0 in Q3 2025.
  • Median Current Leases over the past 5 years was $2.8 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Current Leases: grew 23.8% in 2024 and later tumbled 75.99% in 2025.
  • Heron Therapeutics' Current Leases stood at $2.4 million in 2021, then grew by 11.46% to $2.7 million in 2022, then grew by 14.14% to $3.1 million in 2023, then fell by 1.24% to $3.0 million in 2024, then tumbled by 74.32% to $780000.0 in 2025.
  • The last three reported values for Current Leases were $780000.0 (Q3 2025), $1.5 million (Q2 2025), and $2.3 million (Q1 2025) per Business Quant data.